Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 10
Submit an article Journal homepage
123
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination

Lara Howellsa Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-6579-3011View further author information
ORCID Icon,
Wei Yee Chana Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Emilie Sanchezb Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Jacqueline Hordera Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Fiona Newricka Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Jotham Marfila Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Annabel McMillana Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Brendan Wisniowskia Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Shameem Mahmooda Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Xenofon Papanikolaoua Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Lydia Leea Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK;c Research Department of Haematology, UCL Cancer Institute, London, UKView further author information
,
Ashutosh Wechalekara Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-4406-7237View further author information
ORCID Icon,
Rakesh Popata Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Jonathan Sivea Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Charalampia Kyriakoua Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Ke Xua Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKORCID Iconhttps://orcid.org/0000-0002-2453-4475View further author information
ORCID Icon,
Eleni Nastoulib Department of Clinical Virology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
,
Kwee L. Yonga Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK;c Research Department of Haematology, UCL Cancer Institute, London, UKORCID Iconhttps://orcid.org/0000-0002-6487-276XView further author information
ORCID Icon &
Neil Rabina Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UKView further author information
 show all
Pages 2489-2493 | Received 07 Feb 2022, Accepted 25 Apr 2022, Published online: 14 May 2022

References

  • Cook G, John Ashcroft A, Pratt G, et al. Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020;190(2):e83–e86.
  • Chari A, Samur MK, Martinez-Lopez J, et al. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020;136(26):3033–3040.
  • Ludwig H, Sonneveld P, Facon T, et al. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. Lancet Haematol. 2021;8(12):e934–e946.
  • Sharma A, Bhatt NS, St Martin A, et al. Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021;8(3):e185–e193.
  • Ljungman P, De La Camara R, Mikulska M, et al. COVID-19 and stem cell transplantation; results from the Prospective Survey by the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) and the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Blood. 2020;136(Supplement 1):32–33.
  • Stampfer SD, Goldwater MS, Jew S, et al. Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia. 2021;35(12):3534–3541.
  • Chan WY, Howells L, Wilson W, et al. Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV-19 COVID-19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors. Br J Haematol. 2022;196(3):e21–e26.
  • Van Oekelen O, Gleason CR, Agte S, et al. Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma. Cancer Cell. 2021;39(8):1028–1030.
  • Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J. 2021;11(8):138.
  • Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. Br J Haematol. 2021;195(2):186–193.
  • British Society of Blood and Marrow Transplantation and Cellular Therapy Vaccination Sub-Committee [Internet]. SARS-CoV-2 vaccination following haematopoietic stem cell transplant (HSCT) and chimeric antigen receptor T- cell (CAR-T) therapy. Nov 2021 [cited 20 Dec 2021]. Available from: https://bsbmtct.org/wp-content/uploads/2021/11/BSBMTCT-SARS-CoV-2-vaccination-statement_30Nov2021_FINAL.pdf
  • University of Birmingham, Octave Duo, [Internet]. A phase III, multicentre, randomised controlled trial comparing SARS-CoV-2 re-boost strategies in immunocompromised patients. Oct 2021 [cited 20 Dec 2021] Protocol Version 4.0. Available from: https://www.birmingham.ac.uk/documents/college-mds/trials/crctu/octave/octave-duo-protocol-v4.0-04-10-2021-ci-signed.pdf
  • Aleman A, Upadhyaya B, Tuballes K, et al. Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma. Cancer Cell. 2021;39(11):1442–1444.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.